Valuation: Lakefront Biotherapeutics NV

Market Cap 1.91B 2.13B 1.76B 1.6B 3.03B 200B 3.11B 21.09B 8.4B 107B 8B 7.83B 338B P/E 2026 *
-15.8x
P/E 2027 * -6.41x
Enterprise Value -519M -579M -478M -434M -822M -54.24B -845M -5.73B -2.28B -29.06B -2.17B -2.13B -91.87B EV / Sales 2026 *
-4.43x
EV / Sales 2027 * 4.72x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.27%
1 week+2.65%
Current month+1.94%
1 month+11.50%
3 months+25.77%
6 months+25.98%
Current year+5.29%
1 week 28.5
Extreme 28.5
30.68
1 month 25.56
Extreme 25.56
30.68
Current year 22.32
Extreme 22.32
30.72
1 year 22.32
Extreme 22.32
30.72
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
1/28/26 A Buy

Director

137 0.0002%
1/28/26 A Buy

Director

375 0.0006%
1/28/26 A Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%+2.65%+6.35%-12.10% 2.14B
+0.01%+8.40%+58.48%+69.01% 68.22B
+1.22%+9.56%+15.97%+90.23% 59.82B
+0.24%+1.35%+23.78%+97.55% 56.07B
+0.98%+18.58%+27.87%+111.42% 47.67B
-1.19%+5.09%+29.53%+40.81% 45.95B
-4.59%-1.37%+205.39%+871.94% 43.29B
-3.33%+5.73%+23.28%+47.32% 35.66B
-2.19%-3.71%+90.94%+66.33% 34.73B
+2.49%+13.45%-38.26%+398.91% 25.47B
Average -0.79%+5.31%+44.33%+178.14% 42B
Weighted average by Cap. -0.64%+5.40%+49.84%+178.11%

Financials

2026 *2027 *
Net sales 117M 131M 108M 98.11M 186M 12.26B 191M 1.29B 515M 6.57B 491M 480M 20.76B 84.62M 94.36M 77.98M 70.82M 134M 8.85B 138M 934M 372M 4.74B 354M 347M 14.98B
Net income -40.7M -45.38M -37.51M -34.06M -64.46M -4.25B -66.26M -449M -179M -2.28B -170M -167M -7.21B -213M -237M -196M -178M -337M -22.24B -346M -2.35B -935M -11.91B -890M -871M -37.66B
Net Debt -2.43B -2.71B -2.24B -2.03B -3.85B -254B -3.96B -26.82B -10.69B -136B -10.17B -9.96B -430B -1.51B -1.69B -1.39B -1.27B -2.4B -158B -2.46B -16.69B -6.65B -84.71B -6.33B -6.19B -268B
Projected Income Statement - Annual - Lakefront Biotherapeutics NV
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
196
Date Price Change Volume
10/11/26 €29.48 -1.27% 67,213
09/11/26 €29.86 +0.81% 74,151
06/11/26 €29.62 -1.92% 89,770
05/11/26 €30.20 +1.48% 142,791
04/11/26 €29.76 +3.62% 111,989
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Lakefront Biotherapeutics NV
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
29.86EUR
Average target price
31.46EUR
Spread / Average Target
+5.35%
  1. Stock Market
  2. Stocks
  3. LKFT Stock